Clinical Trial: Renal Efficacy and Safety of the Novel Oral Small-Molecule GLP-1RA HRS-7535 Evaluated in Participants With Chronic Kidney Disease

U.S., June 5 -- ClinicalTrials.gov registry received information related to the study (NCT07625774) titled 'Renal Efficacy and Safety of the Novel Oral Small-Molecule GLP-1RA HRS-7535 Evaluated in Participants With Chronic Kidney Disease' on May 29.

Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group and event-driven phase III clinical trial. The aim of this trial is to confirm the superiority of HRS-7535 over placebo in reducing the risks of renal outcomes and cardiovascular death among participants with chronic kidney disease (CKD) on the basis of standard of care

Study Start Date: July, 2026

Study Type: INTERVENTIONAL

Condition: Chronic Kidney Disease

Intervention: DRUG: HRS-7535

HRS...